O	0	11	Trastuzumab
O	12	16	plus
B-intervention	17	28	vinorelbine
O	29	31	or
B-control	32	38	taxane
I-control	39	51	chemotherapy
O	52	55	for
O	56	60	HER2
O	60	61	-
O	61	75	overexpressing
O	76	86	metastatic
O	87	93	breast
O	94	100	cancer
O	100	101	:
O	102	105	the
O	106	117	trastuzumab
O	118	121	and
O	122	133	vinorelbine
O	134	136	or
O	137	143	taxane
O	144	149	study
O	149	150	.

O	151	154	The
O	155	162	optimal
O	163	174	trastuzumab
O	174	175	-
O	175	180	based
O	181	193	chemotherapy
O	194	201	regimen
O	202	205	for
O	206	210	HER2
O	210	211	-
O	211	225	overexpressing
O	225	226	,
O	227	237	metastatic
O	238	244	breast
O	245	251	cancer
O	252	254	is
O	255	258	not
O	259	264	known
O	264	265	.

O	266	269	The
O	270	281	trastuzumab
O	282	285	and
O	286	297	vinorelbine
O	298	300	or
O	301	307	taxane
O	308	309	(
O	309	317	TRAVIOTA
O	317	318	)
O	319	324	study
O	325	328	was
O	329	330	a
O	331	342	prospective
O	342	343	,
O	344	355	multicenter
O	355	356	,
O	357	367	randomized
O	368	373	trial
O	374	378	that
O	379	382	was
O	383	391	designed
O	392	394	to
O	395	402	compare
O	403	408	these
O	409	417	regimens
O	417	418	.

O	419	427	Eligible
B-eligibility	428	436	patients
I-eligibility	437	440	had
I-eligibility	441	445	HER2
I-eligibility	445	446	-
I-eligibility	446	460	overexpressing
I-eligibility	460	461	,
I-eligibility	462	472	metastatic
I-eligibility	473	479	breast
I-eligibility	480	486	cancer
I-eligibility	487	490	and
I-eligibility	491	494	had
I-eligibility	495	503	received
I-eligibility	504	506	no
I-eligibility	507	512	prior
I-eligibility	513	525	chemotherapy
I-eligibility	526	529	for
I-eligibility	530	538	advanced
I-eligibility	539	546	disease
O	546	547	.

O	548	556	Patients
O	557	561	were
O	562	572	randomized
O	573	574	1
O	574	575	:
O	575	576	1
O	577	579	to
O	580	587	receive
O	588	594	either
O	595	606	trastuzumab
O	607	611	with
O	612	618	weekly
O	619	630	vinorelbine
O	631	638	therapy
O	639	641	or
O	642	648	weekly
O	649	655	taxane
O	656	663	therapy
O	664	665	(
O	665	675	paclitaxel
O	676	678	or
O	679	688	docetaxel
O	689	691	at
O	692	695	the
O	696	708	investigator
O	708	709	'
O	709	710	s
O	711	717	choice
O	717	718	)
O	718	719	.

O	720	730	Originally
O	731	738	planned
O	739	742	for
O	743	746	250
O	747	755	patients
O	755	756	,
O	757	760	the
O	761	766	study
O	767	770	was
O	771	777	closed
O	778	785	because
O	786	788	of
O	789	793	poor
O	794	801	accrual
O	802	806	with
B-total-participants	807	809	81
O	810	819	evaluable
O	820	828	patients
O	828	829	,
O	830	839	including
B-intervention-participants	840	842	41
O	843	851	patients
O	852	855	who
O	856	864	received
O	865	876	vinorelbine
O	877	880	and
B-control-participants	881	883	40
O	884	892	patients
O	893	896	who
O	897	905	received
O	906	912	taxane
O	912	913	.

B-outcome	914	922	Response
I-outcome	923	928	rates
O	929	933	were
B-iv-bin-percent	934	936	51
I-iv-bin-percent	936	937	%
O	938	941	and
B-cv-bin-percent	942	944	40
I-cv-bin-percent	944	945	%
O	946	949	for
O	950	953	the
O	954	965	vinorelbine
O	965	966	/
O	966	977	trastuzumab
O	978	981	arm
O	982	985	and
O	986	989	the
O	990	996	taxane
O	996	997	/
O	997	1008	trastuzumab
O	1009	1012	arm
O	1012	1013	,
O	1014	1026	respectively
O	1027	1028	(
O	1028	1034	Fisher
O	1035	1040	exact
O	1041	1045	test
O	1045	1046	;
O	1047	1048	P
O	1049	1050	=
O	1051	1052	.
O	1052	1054	37
O	1054	1055	)
O	1055	1056	.

O	1057	1060	The
B-outcome	1061	1067	median
I-outcome	1068	1072	time
I-outcome	1073	1075	to
I-outcome	1076	1083	disease
I-outcome	1084	1095	progression
O	1096	1099	was
B-iv-cont-median	1100	1101	8
I-iv-cont-median	1101	1102	.
I-iv-cont-median	1102	1103	5
I-iv-cont-median	1104	1110	months
O	1111	1114	and
B-cv-cont-median	1115	1116	6
I-cv-cont-median	1116	1117	.
I-cv-cont-median	1117	1118	0
I-cv-cont-median	1119	1125	months
O	1126	1129	for
O	1130	1133	the
O	1134	1145	vinorelbine
O	1145	1146	-
O	1147	1150	and
O	1151	1157	taxane
O	1157	1158	-
O	1158	1163	based
O	1164	1168	arms
O	1168	1169	,
O	1170	1182	respectively
O	1183	1184	(
O	1184	1187	log
O	1187	1188	-
O	1188	1192	rank
O	1193	1197	test
O	1197	1198	;
O	1199	1200	P
O	1201	1202	=
O	1203	1204	.
O	1204	1206	09
O	1206	1207	)
O	1207	1208	.

O	1209	1218	Treatment
O	1219	1223	with
O	1224	1230	either
O	1231	1238	regimen
O	1239	1248	generally
O	1249	1252	was
B-outcome	1253	1257	well
I-outcome	1258	1267	tolerated
O	1267	1268	,
O	1269	1277	yielding
O	1278	1288	comparable
O	1289	1294	rates
O	1295	1297	of
O	1298	1308	neurologic
O	1309	1312	and
O	1313	1329	gastrointestinal
O	1330	1338	toxicity
O	1338	1339	.

O	1340	1351	Vinorelbine
O	1351	1352	-
O	1352	1357	based
O	1358	1367	treatment
O	1368	1371	was
O	1372	1382	associated
O	1383	1387	with
O	1388	1392	more
B-outcome	1393	1399	anemia
I-outcome	1400	1403	and
I-outcome	1404	1415	neutropenia
O	1416	1419	and
O	1420	1424	with
B-iv-bin-abs	1425	1426	2
O	1427	1435	episodes
O	1436	1438	of
B-outcome	1439	1453	cardiotoxicity
O	1453	1454	.

O	1455	1461	Taxane
O	1461	1462	-
O	1462	1467	based
O	1468	1475	therapy
O	1476	1479	was
O	1480	1490	associated
O	1491	1495	with
O	1496	1500	more
B-outcome	1501	1513	dermatologic
I-outcome	1514	1522	toxicity
O	1522	1523	,
B-outcome	1524	1532	myalgias
O	1532	1533	,
O	1534	1537	and
B-outcome	1538	1543	fluid
I-outcome	1544	1553	retention
O	1553	1554	.

O	1555	1559	Both
O	1560	1571	vinorelbine
O	1571	1572	/
O	1572	1583	trastuzumab
O	1584	1587	and
O	1588	1594	taxane
O	1594	1595	/
O	1595	1606	trastuzumab
O	1607	1617	treatments
O	1618	1622	were
O	1623	1629	active
O	1630	1632	as
O	1633	1638	first
O	1638	1639	-
O	1639	1643	line
O	1644	1651	therapy
O	1652	1655	for
O	1656	1660	HER2
O	1660	1661	-
O	1661	1669	positive
O	1669	1670	,
O	1671	1681	metastatic
O	1682	1688	breast
O	1689	1695	cancer
O	1696	1699	and
O	1700	1703	had
O	1704	1714	comparable
B-outcome	1715	1720	rates
I-outcome	1721	1723	of
I-outcome	1724	1732	efficacy
I-outcome	1733	1736	and
I-outcome	1737	1749	tolerability
O	1749	1750	.

O	1751	1754	The
O	1755	1765	toxicities
O	1766	1774	observed
O	1775	1779	were
O	1780	1783	the
O	1784	1790	result
O	1791	1793	of
O	1794	1804	recognized
O	1805	1809	side
O	1810	1817	effects
O	1818	1828	associated
O	1829	1833	with
O	1834	1838	each
O	1839	1841	of
O	1842	1845	the
O	1846	1858	chemotherapy
O	1859	1865	agents
O	1866	1869	and
O	1870	1879	schedules
O	1879	1880	.

O	1881	1886	These
O	1887	1891	data
O	1892	1895	can
O	1896	1902	inform
O	1903	1912	treatment
O	1913	1921	decision
O	1922	1928	making
O	1929	1931	in
O	1932	1936	this
O	1937	1945	clinical
O	1946	1953	setting
O	1953	1954	.
